<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01946061</url>
  </required_header>
  <id_info>
    <org_study_id>4-2013-0452</org_study_id>
    <nct_id>NCT01946061</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced gastric cancer have showed poor prognosis. Only 81% of the patients&#xD;
      could underwent curative surgery. In those, about 60% of patients would survive after 5 years&#xD;
      from the surgery. As a result, role of chemotherapy has been increased. In ACTS-GC trial, S-1&#xD;
      adjuvant therapy after D2 gastrectomy increased overall survival rate in advanced gastric&#xD;
      cancer patients. However, subgroup analysis showed that S-1 adjuvant therapy was insufficient&#xD;
      in patients with stage III or IV (according to the AJCC 6th criteria) gastric cancer. In&#xD;
      addition, CLASSIC trial demonstrated that oxaliplatin plus capecitabine adjuvant therapy&#xD;
      could increase disease-free survival after D2 gastrectomy in advanced gastric cancer&#xD;
      patients. Notwithstanding these trial, optimal adjuvant regimen of advanced gastric cancer&#xD;
      has not been established. We aimed to evaluate efficacy of S-1 plus oxaliplatin as adjuvant&#xD;
      chemotherapy after D2 gastrectomy in stage III (according to the AJCC 7th criteria) gastric&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was stopped because of difficulties of supplying the drug.&#xD;
  </why_stopped>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>3 years from the surgery</time_frame>
    <description>3-year disease-free survival will be assessed by imaging study including CT and PET.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 plus oxaliplatin</intervention_name>
    <description>Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age, between 19 and 75&#xD;
&#xD;
          -  Histologically proven advanced gastric cancer&#xD;
&#xD;
          -  R0 resection after D2 gastrectomy&#xD;
&#xD;
          -  Stage III (according to the AJCC 7th criteria)&#xD;
&#xD;
          -  ECOG status 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignancy history other than gastric cancer&#xD;
&#xD;
          -  Previous chemotherapy history for gastric cancer&#xD;
&#xD;
          -  Previous radiotherapy history for gastric cancer&#xD;
&#xD;
          -  Pregnancy or breast milk feeding&#xD;
&#xD;
          -  Grade 3 or more of neuropathy&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Severe hepatic dysfunction&#xD;
&#xD;
          -  Severe renal dysfunction&#xD;
&#xD;
          -  Severe bone marrow dysfunction&#xD;
&#xD;
          -  Significant neurologic or psychologic disease&#xD;
&#xD;
          -  Inadequate condition for receiving chemotherapy due to significant systemic disease&#xD;
&#xD;
          -  Patients who receives drugs which can be interacted with S-1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severnace Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.</citation>
    <PMID>17978289</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2013</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxaliplatin, S-1, Gastric cancer, Adjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

